Momentum Pharma is bringing its clinical research expertise to Australia as part of a new international tour, following its landmark achievement as the first organisation to be awarded the Business Process Quality Certification (BPQC) by the International Accrediting Organisation for Clinical Research (IAOCR).
The Australian leg of the tour will commence on the evening of 17th July at the British Consulate-General in Sydney. The exclusive, invite-only event will feature a panel discussion and networking session, where Momentum Pharma will join just three other key industry sponsors. Melissa Melton, Co-Founder and CEO of Momentum Pharma, is confirmed as a panel speaker for the evening.
Full event details: https://iaocr.com/resources/australia-new-zealand-2025/
The Momentum Pharma tour will unfold with additional stops in Melbourne, Brisbane and Adelaide. This will provide opportunities for both Co Founders of Momentum Pharma, Melissa Melton CEO and Jon Melton COO, to meet and address clinical research industry leaders in the region.
Speaking about the tour Melissa Melton says, “I’m honoured to be a featured panel speaker at the upcoming international event, Advancing Quality in Clinical Research Operations – Global Best Practices & Insights, taking place on 17 July 2025 at the British General Consulate in Sydney, Australia. This influential event will convene experts from across the pharmaceutical, biotech, CRO, and academic sectors to focus on the importance of the need for multinational teams to operate under alignment with global quality standards. This is essential to ensure that we meet globally accepted benchmarks for ethical and scientific quality at a time when clinical research is coming under ever more public and governmental scrutiny.
Throughout the past 26 years, I’ve dedicated my career to elevating standards in clinical research, both through my own work in the industry and now as Co-Founder and CEO of Momentum Pharma. My aim is to drive operational excellence, regulatory compliance, and patient-centric innovation across global trials.
Momentum Pharma was proud to be the first organisation to achieve the Business Process Quality Certification, which has added another layer of credibility and trust to our CRO reputation. I view the certification as an essential accomplishment for CROs, sites and independent consultants in the industry who are seeking assurance of operational excellence. As clinical research continues to evolve, it’s critical that we share insights, challenge norms, and collectively raise the bar for quality and efficiency.
As we at Momentum Pharma look to deepen our business connections throughout Australia and bring new clinical trials to the region, I am more focused than ever on the ongoing journey of striving for excellence in our operations, global teams and partners.”
The event on the 17th July is hosted by Jacqueline Johnson North, Founder & Chief Executive of the International Accrediting Organization for Clinical Research (IAOCR). The panel session will explore the development of best-practice quality standards that are shaping the global clinical research ecosystem and what that means for organisations and consumers in Australia.
The key themes underpinning this event include access and inclusion in clinical trials, the vital role of diverse sites and vendors in facilitating this, and how sharing best-practice and enabling meaningful partnerships is essential to building the confidence and competence required to create and deliver genuine patient-centric research environments.
Clinical research is a truly international industry, requiring global best practices, robust quality standards and collaboration. As the leading provider of quality assurance, certifications and accreditations for the industry, IAOCR is trusted in over 40 countries. IAOCR is proud to play a key role in connecting a fast-growing community of internationally qualified accredited professionals and certified clinical research organisations that are dedicated to delivering high quality research, and ensuring best-in-class high research journeys and experiences for patients worldwide.
